The genetic influence of the brain-derived neurotrophic factor Val66Met polymorphism in chronic low back pain

Angela Shiratsu Yamada 1*, Flavia Tasmim Techera Antunes 1, Camila Ferraz 2, Alessandra Hubner de Souza 3 and Daniel Simon 1,2

Abstract

Background: The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP).

Methods: A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism.

Results: The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP.

Conclusion: The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

Keywords: Central sensitization, Catastrophizing, BDNF, Polymorphism, Single nucleotide polymorphism, Val66Met

Background

In the populations suffering from chronic pain, low back pain is one of the most prevalent musculoskeletal disorders, affecting 70 to 85% of adults at some point in their life [1]. Regardless of the primary or secondary pathology, the consequences of persistent pain include the fear of movement, pain catastrophizing, anxiety, and central sensitization. These outcomes appear to be the major contributors of pain and disability under these conditions [2, 3].

It is well known that the experience of pain is influenced by biological, psychological, and behavioral factors. Among the biological factors, there is a growing interest in the genetic aspects, in an attempt to explain some of the differences in the pain responses between individuals [4]. Studies have considered that the genetic factors represent more than a 50% susceptibility to chronic low back pain (CLBP) [5], whereas the variation in the genes that are involved in pain perception and its modulation, transduction, transmission, and conduction by the nervous system can result in variabilities in the experience of pain [6].

The brain-derived neurotrophic factor (BDNF) is a neurotrophin that is involved in neurogenesis and synaptic plasticity in the central nervous system. The
Val66Met polymorphism (c.196G > A, dbSNP: rs6265) of the BDNF gene represents the replacement of valine (Val) with a methionine (Met) at codon 66. This substitution in the BDNF pro-region changes the intracellular trafficking and packaging of the pro-BDNF, its availability in the synaptic cleft, and the deterioration of synaptic plasticity, thus decreasing the BDNF secretion [7]. The Val66Met polymorphism has been considered as a marker of vulnerability to pain. Individuals with the Met allele were more likely to have chronic pain when associated with the presence and severity of chronic musculoskeletal pain in multiple sites, in studies that investigated individuals with childhood or recent life stress [8], and with an increased risk of chronic postoperative pain [9]. However, the studies on the role of BDNF, both in relation to the genotypes, their expression, and the serum protein levels in chronic pain, still show inconclusive results.

Most treatment strategies for CLBP are still based on the biomedical model, that is, structural-anatomical-mechanical [10]. However, the biopsychosocial model is based on a dynamic relationship between the biological changes, psychological status, and social context, emphasizing that these factors have different roles in chronic pain, disability, and emotional maladjustment [11]. Therefore, the present study aimed to investigate the association of the single nucleotide polymorphism (SNP) Val66Met of the BDNF gene with clinical and biopsychosocial factors in patients with CLBP.

Methods
All of the procedures complied with the requirements of Resolution 466/12 of the National Health Council. The data collection occurred after the approval by the Research Ethics Committee from the Lutheran University of Brazil (ULBRA), under protocol number 2.254.800. All of the patients gave written informed consent before their participation.

Subjects
The study was carried out in Palmas (Tocantins, Brazil), at the Lutheran University Center of Palmas (CEULP/ULBRA), in the community service center, the Clinical School of Physiotherapy (CSP). The eligibility criteria were individuals over 18 years of age of both genders, who had CLBP for over 3 months.

Procedure
The individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, such as the Brief Inventory of Pain (BIP) [12]; the Central Sensitization Inventory (CSI) [13]; the Roland Morris Disability Questionnaire (RMDQ) [14]; the Tampa Scale for Kinesiophobia [15]; the Pain Catastrophizing Scale (PCS) [16]; and the Hospital Anxiety and Depression Scale (HADS) [17]. Afterward, 5 ml of peripheral blood was collected using sodium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant, and it was then frozen.

Genetic analyses
The total DNA was purified from the blood samples and the Val66Met SNP (rs6265) was genotyped through the real-time polymerase chain reaction (PCR) when using TaqMan® SNP Genotyping assays (Thermo Fisher Scientific; catalog 4,351,379, assay ID: C__11592758_10). All of the assays were run on a StepOnePlus™ system (Bio-systems Inc., Foster City, USA).

Statistical analyses
The data was analyzed using descriptive statistics, and by employing mean, standard deviations, and percentages through the SAS version 9.4 program. A bivariate analysis was performed to compare the variables under study in relation to the genotypes of Val66Met. For the qualitative variables, the Chi-square test was applied, and for the quantitative variables, the Mann-Whitney non-parametric test was applied. The allele frequencies were determined by direct counting of the alleles. The departures from the Hardy-Weinberg equilibrium were evaluated by the Chi-square test. \( p < 0.05 \) was considered statistically significant.

Results
The sample was composed of 107 patients (56.5% women) with CLBP. The clinical and demographic characteristics of the sample are shown in Table 1. Briefly, the mean age was 46.2 ± 14.3 years, the BMI was 26.8 ± 5.1 kg/m² (26.7% with obesity), with a score of 49.6 ± 14.4 in the CSI assessment, presuming central sensitization, and a score of 15.7 ± 5.3 in the RMDQ, presuming disabilities. The analysis of the BIP showed that the patients had pain in at least roughly nine body regions, summing the low back. The Tampa scores were considered moderate (45.6 ± 7.8). The PCS scores evidenced rumination thoughts. In addition, mild anxiety was observed according to the HADS scores.

In the present study, it was observed that 26 (24.3%) patients were carriers of the Met allele of SNP Val66Met in the BDNF gene. There were no significant associations between the Val66Met genotypes and either the quantitative (Table 2) or the qualitative variables studied (Table 3).

Discussion
The present study found no associations between the BDNF Val66Met genotypes and the biopsychosocial phenotypes in patients with CLBP. The Val66Met
polymorphism is the most studied in the BDNF gene and it has been investigated in several pathological conditions in humans [18–20]. The Val66Met polymorphism has also been associated with the methylation patterns, and it is being related to the epigenetic regulation of the BDNF gene [21]. From a biological perspective, it is known that the responses of an organism’s experience to the external environment can be reflected in the epigenetic changes. Thus, the gene expression could also be regulated by the epigenetic modifications to the chromatin structure and the patterns of DNA methylation. These adaptations can modify, among others, neuronal morphology and the activity to produce changes in behavior [22, 23]. Alterations in the chromatin structure represent mechanisms by which pain can be converted gradually and progressively into the pathological processes of neuro-inflammation, central sensitization, and ultimately, chronic pain syndromes [24].

The averages of the disabilities of the patients in the present study due to CLBP were classified as moderate from the RMDQ. It is recommended to consider an assessment of the multidimensional nature of CLBP in the management of pain [25]. This could be physical (for example, disability and body composition), psychological (for example, kinesiophobia, fear-avoidance, pain catastrophizing, pain self-efficacy, depression, anxiety, and sleep quality), and/or social (social functioning and work absenteeism) factors.

Most of the evaluated patients presented overweight/obesity conditions. Adiposity may modulate pain through peripheral sensitization from increased systemic inflammation [26]. In addition, it was observed that the increased fat infiltration of the paraspinal musculature could be associated with a compromised function of the muscles that control and support the low back [27, 28]. The findings from the BIP data also showed that the worst pain affected the normal work of the patients, restricting the performance of the activities of daily living.

The individuals in the present study reported being physically inactive. The relationship between a cluster of unhealthy lifestyle behaviors (smoking, alcohol drinking, physical activity, weight control, breakfast, snacking, and sleep) and low back pain (LBP) was investigated in a cross-sectional study of over 400,000 Japanese adults showing an association of this cluster with an increased risk of LBP, regardless of age and BMI [29]. Moreover, chronic pain is at least partly attributed to a sedentary and inactive lifestyle and it could be recognized as a lifestyle-related disease. Physical activity/inactivity may also determine the genetic/epigenetic and neural factors encoded in the brain [30]. A single session of exercise and regular physical activity induce changes in the genes that regulate the nociceptive processes, the learning of fear, and the stress responses, as well as those that are involved in the pathophysiology of chronic diseases [31].

In the current study, the mean of the total scores in Tampa was moderate. Fear can be learned through associative learning. Previous study reported that conditioning to fear was able of inducing a rapid increase in methylation of the BDNF gene in the hippocampus, and it occurred during the consolidation of fear [32]. It is well known that the fear and the avoidance of particular movements could add to a disability, but the assessment and removal of these barriers to movement might, therefore, reduce the disability [33]. A psychological factor that distinctly predicts changeability in the perception of pain and the development of moderate kinesiophobia is pain catastrophizing [34]. In the present study, the CLBP patients presented scores that suggested rumination and helplessness thoughts, besides mild anxiety and central sensitization. Anxiety and stress predict chronic pain in

### Table 1 Characteristics of the sample studied

| Variable                  | Mean   | SD     |
|---------------------------|--------|--------|
| Age                       | 46.24  | 14.27  |
| Subjective assessment of stress | 5.84   | 2.39   |
| BMI                       | 26.82  | 5.14   |
| Total CSI score           | 49.6   | 14.39  |
| Total RMDQ score          | 15.7   | 5.3    |
| BIP pain intensity        |        |        |
| Worst                     | 6.49   | 2.59   |
| Least                     | 3.16   | 2.45   |
| Average                   | 5.37   | 2.26   |
| Now                       | 4.56   | 3.02   |
| BIP interference          |        |        |
| General activity          | 5.83   | 3.34   |
| Mood                      | 5.5    | 3.52   |
| Walking                   | 5.41   | 3.32   |
| Normal work               | 5.97   | 3.7    |
| Relations                 | 3.58   | 3.34   |
| Sleep                     | 5.44   | 3.46   |
| Enjoyment of life         | 4.48   | 3.63   |
| Σ pain-body regions       | 8.95   | 6.04   |
| Total Tampa score         | 45.61  | 7.82   |
| Total PCS score           | 2.17   | 1.2    |
| PCS rumination            | 2.68   | 1.33   |
| PCS helplessness          | 1.53   | 1.31   |
| HADS-anxiety              | 9.04   | 3.47   |
| HADS-depression           | 6.91   | 3.98   |

*BMI body mass index, BPI the brief inventory of pain, CSI central sensitization inventory, HADS hospital anxiety and depression scale, PCS pain catastrophizing scale, RMDQ Rolland-Morris disability questionnaire, SD standard deviation*
the long term and they might mediate the vulnerability to pain [35]. Thus, there is plausibility that the extent of central sensitization symptoms in people with non-specific LBP might be associated with the pre-morbid trait anxiety sub-types and the abnormal trait sensory processing profiles [36, 37]. Moreover, depression and anxiety are barriers to treatment adherence in various chronic pain conditions, such as low back pain [38].

Although 74% of the patients in the present study reported themselves to be active/employed, they described the pain during a month at an intense level and with chronicity for up to 13 months. This is important since CLBP is also considered responsible for absenteeism at work, and with high rates of disability, generating high costs for the health system, social security, and society in general [39]. Moreover, non-opioids were the main medication used, and most of the patients reported a modest relief of the pain with the medication.

The importance of behavioral approaches to back pain management does not preclude the continuing need to investigate mechanisms and the potential biological determinants of non-specific low back pain [40]. The relative importance of the genetic factors in human musculoskeletal pain conditions, such as CLBP, painful temporomandibular joint disorders, fibromyalgia, and chronic widespread pain, is becoming clearer. Several polymorphisms in the genes are contributing to serotonergic and adrenergic pathways that are associated with musculoskeletal pain [41]. Despite studies demonstrating evidence that the BDNF Val66Met polymorphism influences the cortical processing of experimental electrical pain stimuli in an indirect manner [4], or in pain catastrophizing [42], the findings in the present study did not show the influence of this polymorphism in chronic pain complaints.

Certain limitations must be considered in the interpretation of the current study’s findings. First, the

Table 2 Comparison of the quantitative variables according to the BDNF Val66Met genotypes

| Variable                      | Val/Val (n = 81) | Val/Met (n = 26) | P-value |
|-------------------------------|-----------------|-----------------|---------|
| Age                           | 46.2 ± 14.3     | 46.5 ± 14.6     | 0.73    |
| Subjective assessment of stress | 5.9 ± 2.5     | 5.8 ± 2.1       | 0.62    |
| BMI                           | 27.1 ± 5.2      | 26.4 ± 4.9      | 0.47    |
| Total CSI score               | 50.3 ± 14.6     | 48.0 ± 13.9     | 0.50    |
| Total RMDQ score              | 15.6 ± 5.5      | 15.8 ± 4.8      | 0.99    |
| BIP pain intensity            |                 |                 |         |
| Worst                         | 6.5 ± 2.5       | 6.4 ± 2.9       | 0.97    |
| Least                         | 3.2 ± 2.4       | 2.8 ± 2.4       | 0.42    |
| Average                       | 5.4 ± 2.1       | 5.2 ± 2.8       | 0.52    |
| Now                           | 4.6 ± 3.0       | 4.2 ± 3.0       | 0.45    |
| BIP interference              |                 |                 |         |
| General activity              | 5.9 ± 3.4       | 5.4 ± 3.2       | 0.44    |
| Mood                          | 5.7 ± 3.5       | 4.9 ± 3.7       | 0.36    |
| Walking                       | 5.4 ± 3.2       | 5.3 ± 3.5       | 0.96    |
| Normal work                   | 6.1 ± 3.8       | 5.3 ± 3.4       | 0.16    |
| Relation                      | 3.6 ± 3.4       | 3.5 ± 3.2       | 0.92    |
| Sleep                         | 5.4 ± 3.6       | 5.3 ± 3.2       | 0.76    |
| Enjoyment of life             | 4.3 ± 3.7       | 5.1 ± 3.5       | 0.34    |
| Summation of pain body regions | 9.0 ± 5.0       | 8.7 ± 8.8       | 0.07    |
| Total Tampa score             | 45.6 ± 8.1      | 45.9 ± 7.2      | 0.87    |
| Total PCS score               | 2.2 ± 1.2       | 1.9 ± 1.1       | 0.32    |
| PCS rumination                | 2.8 ± 1.4       | 2.3 ± 1.1       | 0.18    |
| PCS helplessness              | 1.5 ± 1.3       | 1.4 ± 1.4       | 0.51    |
| HADS anxiety                  | 9.3 ± 3.5       | 8.4 ± 3.5       | 0.52    |
| HADS depression               | 7.1 ± 3.8       | 6.6 ± 4.4       | 0.35    |

Values are shown as mean ± standard deviation
BMI body mass index, BPI the brief inventory of pain, CSI central sensitization inventory, HADS hospital anxiety and depression scale, PCS pain catastrophizing scale, RMDQ Rolland-Morris disability questionnaire
P-value for the Mann-Whitney test
Table 3  Comparison of the qualitative variables according to the BDNF Val66Met genotypes

| Genotype             | Val/ Val N (%) | Val/Met N (%) | P-value |
|----------------------|----------------|---------------|---------|
| Gender               |                |               |         |
| Female               | 45 (55.6)      | 16 (61.5)     | 0.59    |
| Male                 | 36 (44.4)      | 10 (38.6)     |         |
| Civil status         |                |               |         |
| Living alone         | 42 (51.8)      | 11 (42.3)     | 0.40    |
| Living with partner  | 39 (48.2)      | 15 (57.7)     |         |
| Ethnicity            |                |               |         |
| White                | 14 (18.2)      | 8 (34.8)      | 0.14    |
| Brown                | 46 (59.7)      | 13 (56.5)     |         |
| Black                | 17 (22.1)      | 2 (8.7)       |         |
| Schooling            |                |               |         |
| Until high school    | 63 (77.8)      | 16 (64.0)     | 0.17    |
| Complete high school | 18 (22.2)      | 9 (36.0)      |         |
| Have children        |                |               |         |
| No                   | 19 (23.5)      | 6 (23.1)      | 0.97    |
| Yes                  | 62 (76.5)      | 20 (76.9)     |         |
| Healthy              |                |               |         |
| Good, very good, or great | 35 (44.3) | 12 (46.1)   | 0.87    |
| Regular, bad, or lousy | 44 (55.7) | 14 (53.9)   |         |
| Chronicity pain      |                |               |         |
| 3–12 months          | 21 (25.9)      | 5 (19.2)      | 0.31    |
| 13–60 months         | 27 (33.3)      | 13 (50.0)     |         |
| > 60 months          | 33 (40.8)      | 8 (30.8)      |         |
| Pain intensity       |                |               |         |
| Least                | 8 (9.9)        | 4 (15.4)      | 0.62    |
| Moderate             | 14 (17.3)      | 3 (11.5)      |         |
| Intense              | 59 (72.8)      | 19 (73.1)     |         |
| Pain duration in the month |            |               |         |
| Intermittent         | 37 (46.2)      | 15 (65.2)     | 0.11    |
| Constant             | 43 (53.8)      | 8 (34.8)      |         |
| Comorbidities        |                |               |         |
| No                   | 46 (56.8)      | 16 (61.5)     | 0.67    |
| Yes                  | 35 (43.2)      | 10 (38.5)     |         |
| Physical activity    |                |               |         |
| Inactive             | 55 (67.9)      | 18 (69.2)     |         |
| Insufficiently active| 8 (9.9)        | 4 (15.4)      | 0.80    |
| Moderately active    | 13 (16.0)      | 3 (11.5)      |         |
| Vigorously active    | 5 (6.2)        | 1 (3.9)       |         |
| Smoking              |                |               |         |
| No                   | 68 (91.9)      | 21 (91.3)     | 0.93    |
| Yes                  | 6 (8.1)        | 2 (8.7)       |         |
| Alcoholism           |                |               |         |
| No                   | 66 (89.2)      | 22 (95.7)     | 0.35    |
| Yes                  | 8 (10.8)       | 1 (4.3)       |         |
Table 3: Comparison of the qualitative variables according to the BDNF Val66Met genotypes (Continued)

| Genotype                                                                 | Val/ Val N (%) | Val/Met N (%) | P-value |
|--------------------------------------------------------------------------|----------------|---------------|---------|
| Satisfaction                                                             |                |               |         |
| Unsatisfied or a little satisfied                                        | 33 (51.6)      | 9 (40.9)      | 0.39    |
| Satisfied or much satisfied                                              | 31 (48.4)      | 13 (59.1)     |         |
| Occupational situation                                                   |                |               |         |
| Active/employed                                                          | 62 (76.5)      | 18 (69.2)     | 0.45    |
| Unemployed                                                               | 19 (23.5)      | 8 (30.8)      |         |
| Low back pain in family history                                          |                |               |         |
| No                                                                       | 36 (44.4)      | 12 (46.2)     | 0.88    |
| Yes                                                                      | 45 (55.6)      | 14 (53.8)     |         |
| Overweight/obesity                                                       |                |               |         |
| No                                                                       | 32 (41.0)      | 11 (42.3)     | 0.91    |
| Yes                                                                      | 46 (59.0)      | 15 (57.7)     |         |
| CSI                                                                      |                |               |         |
| No                                                                       | 14 (17.3)      | 4 (15.4)      | 0.82    |
| Yes                                                                      | 67 (82.7)      | 22 (84.6)     |         |
| RMDQ                                                                     |                |               |         |
| No                                                                       | 28 (34.6)      | 9 (34.6)      | 0.97    |
| Yes                                                                      | 53 (65.4)      | 17 (65.4)     |         |
| Medication                                                               |                |               |         |
| Non opioid                                                               | 33 (62.3)      | 12 (80.0)     | 0.20    |
| Weak opioid                                                              | 20 (37.7)      | 3 (20.0)      |         |
| Medication frequency                                                     |                |               |         |
| Every 6 h                                                                | 35 (66.0)      | 7 (50.0)      | 0.27    |
| If there is pain                                                         | 18 (34.0)      | 7 (50.0)      |         |
| Start of medication                                                      |                |               |         |
| 12 months ago                                                            | 32 (68.1)      | 8 (80.0)      | 0.75    |
| 13–60 months                                                            | 7 (14.9)       | 1 (10.0)      |         |
| More than 60 months                                                      | 8 (17.0)       | 1 (10.0)      |         |
| Relief of pain with medication                                           |                |               |         |
| 50% relief                                                               | 32 (62.8)      | 5 (45.5)      | 0.29    |
| More than 50% relief                                                     | 19 (37.2)      | 6 (54.5)      |         |
| Tampa score                                                              |                |               |         |
| Light                                                                    | 7 (8.6)        | 2 (7.7)       | 0.89    |
| Moderate                                                                 | 47 (58.1)      | 14 (53.8)     |         |
| Critical                                                                 | 27 (33.3)      | 10 (38.5)     |         |
| HADS-anxiety                                                            |                |               |         |
| No                                                                       | 34 (42.0)      | 11 (42.3)     | 0.98    |
| Yes                                                                      | 47 (58.0)      | 15 (57.7)     |         |
| HADS-depression                                                          |                |               |         |
| No                                                                       | 53 (65.4)      | 20 (76.9)     | 0.27    |
| Yes                                                                      | 28 (34.6)      | 6 (23.1)      |         |

CSI: central sensitization inventory, HADS: hospital anxiety and depression scale, RMDQ: Rolland-Morris disability questionnaire

P-value for the Chi-square test
statistical power of the sample size that was analyzed was limited. Second, this was a cross-sectional study, which might limit the causality identification of the demographic and clinical variables that were investigated. Third, to have a better understanding of the role of BDNF in CLBP, it would be important to investigate the correlation between the genotypes and the serum levels.

**Conclusion**

The present study showed no association between the Val66Met BDNF polymorphism with the clinical and biopsychosocial characteristics in patients with CLBP. However, further studies are still needed to elucidate if the BDNF Val66Met polymorphism could influence other distinct subjective pain experience outcomes in different samples with CLBP.

**Acknowledgements**

The authors would like to thank the patients who participated in the study.

**Authors' contributions**

A.S. Yamada, A.H. de Souza, and D. Simon designed the study. A.S. Yamada and C. Ferraz collected the data. A.S. Yamada and D. Simon performed the statistical analyses. A.S. Yamada, A.H. de Souza, and D. Simon contributed to the final version of the manuscript. All of the authors have reviewed and approved the final version of the article, including the authorship list.

**Funding**

This research was supported by grants from the Brazilian agency Coordination for the Improvement of Higher Education Personnel from Brazil (CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Finance Code 001). The funding source had no involvement in the study design, collection, analysis and interpretation of data, writing of the report, and the decision to submit the article for publication.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Research Ethics Committee of the Lutheran University of Brazil (ULBRA), under protocol number 2.254.800. All subjects signed the informed consent form. The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Molecular and Cellular Biology Applied to Health, Lutheran University of Brazil (ULBRA), Canoas, Brazil. 2. Lutheran University of Brazil (ULBRA), Canoas, Brazil. 3. Biochemical and Molecular Pharmacology from the Federal University of Minas Gerais, Belo Horizonte, Brazil.

Received: 15 February 2021 Accepted: 27 April 2021

**References**

1. Becker A, Held H, Redaeili M, Strauch K, Chenot JF, Leonhardt C, et al. Low back pain in primary care: costs of care and prediction of future health care utilization. Spine. 2010;35(18):1714–20. https://doi.org/10.1097/BRS.0b013e3181c6d56f

2. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581–624. https://doi.org/10.1037/0033-2909.133.4.581.

3. Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg. 2004;99(5):1510–20. https://doi.org/10.1213/01.ANE.0000133383.17666.3A.

4. Vossen H, Kerst G, Rutten B, van Ors J, Hermens H, Loubreg R. The genetic influence on the cortical processing of experimental pain and the moderating effect of pain status. PLoS One. 2010;5(10):e13641. https://doi.org/10.1371/journal.pone.0013641.

5. MacGregor AJ, Andrew T, Sambrook J, Ferraz MB, Goldenberg J. Translation, adaptation and validation of the Roland-Morris questionnaire - Brazil Roland-Morris. Braz J Med Biol Res. 2001;34(2):203–11. https://doi.org/10.1590/S0100-879X2001000300019.

6. Omair A, Mannion AF, Holden M, Fairbank J, Lie BA, Hägg O, et al. Catechol-O-methyltransferase (COMT) gene polymorphisms are associated with baseline disability but not long-term treatment outcome in patients with chronic low back pain. Eur Spine J. 2015;24(11):2425–31. https://doi.org/10.1007/s00586-015-3866-5.

7. Harrisberger F, Smirenska R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Behav Rev. 2015;55:107–1. https://doi.org/10.1016/j.neubiorev.2015.04.017.

8. Gath G, Milaneschi Y, Jansen R, Elzinga BM, Dekker J, Penninx BW. The brain-derived neurotrophic factor pathway, life stress, and chronic multi-site musculoskeletal pain. Mol Pain. 2016;12:174480691664783. https://doi.org/10.1177/174480691664783.

9. Tian Y, Liu X, Jia M, Yu H, Lichtner P, Shi Y, et al. Targeted genotyping identifies susceptibility locus in brain-derived Neurotrophic factor gene for chronic postural pain. Anesthesiology. 2018;128(3):587–97. https://doi.org/10.1097/ALN.0000000000000197.

10. Descomps MB, Bartz PT, Fiegenbaum TR, Candotti CT, Vieira A. Treatment of adult female twins. Arthritis Rheum. 2004;51(2):160–7. https://doi.org/10.1002/art.20326.

11. Descomps MB, Bartz PT, Fiegenbaum TR, Candotti CT, Vieira A. Treatment of adult female twins. Arthritis Rheum. 2004;51(2):160–7. https://doi.org/10.1002/art.20326.

12. Ferreira KA, Teixeira MJ, Mendonza TR, Cleeland CS. Validation of brief pain inventory to Brazilian patients with pain. Support Care Cancer. 2011;19(4):809–2950/170003626012019.

13. Vossen H, Kerst G, Rutten B, van Ors J, Hermens H, Loubreg R. The genetic influence on the cortical processing of experimental pain and the moderating effect of pain status. PLoS One. 2010;5(10):e13641. https://doi.org/10.1371/journal.pone.0013641.

14. MacGregor AJ, Andrew T, Sambrook J, Ferraz MB, Goldenberg J. Translation, adaptation and validation of the Roland-Morris questionnaire - Brazil Roland-Morris. Braz J Med Biol Res. 2001;34(2):203–11. https://doi.org/10.1590/S0100-879X2001000300019.

15. Descomps MB, Bartz PT, Fiegenbaum TR, Candotti CT, Vieira A. Treatment of adult female twins. Arthritis Rheum. 2004;51(2):160–7. https://doi.org/10.1002/art.20326.

16. Junior JS, Nicholas MK, Pereira IA, Pimenta CAM, Asghari A, Cruz RM. Validation of the pain-related Catastrophizing thoughts scale. Acta Ortop. 2008;15(1):31–6.
17. Castro MMC, Quarrantini L, Batista-Neves S, Kaychete DC, Daltro C, Miranda-Scippa A. Validity of the hospital anxiety and depression scale in patients with chronic pain. Rev Bras Anestesiol. 2006;56(5):470–7. https://doi.org/10.1590/S0034-70942006000500005.

18. Shen T, You Y, Joseph C, Mizzi M, Klistorner A, Graham SL, et al. BDNF polymorphism: a review of its diagnostic and clinical relevance in neurodegenerative disorders. Aging Dis. 2018;9(3):523–36. https://doi.org/10.1007/s42358-017-0171-7

19. Tsai SJ. Critical issues in BDNF Val66Met genetic studies of neuropsychiatric disorders. Front Mol Neurosci. 2018;11:156. https://doi.org/10.3389/fnmol.2018.00156.

20. Lin CC, Huang TL. Brain-derived neurotrophic factor and mental disorders. Biomarkers. 2020;43(2):134–42. https://doi.org/10.1080/13547860.2020.1806101.

21. Ursini G, Cavalleri T, Fazio L, Angrisano T, Iacovelli L, Porcelli A, et al. BDNF rs6265 methylation and genotype interact on risk for schizophrenia. Epigenetics. 2016;11(1):11–23. https://doi.org/10.1080/15592294.2015.117736.

22. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407–12. https://doi.org/10.1038/nature05915.

23. Kress M, Hüttenhofer A, Landry M, Kuner R, Favereaux A, Greenberg D, et al. MicroRNAs in nociceptive circuits as predictors of future clinical applications. Front Mol Neurosci. 2013;6:33. https://doi.org/10.3389/fnmol.2013.00033.

24. Descalzi G, Ikegami D, Ushijima T, Nestler EJ, Zachariou V, Nairta M. Epigenetic mechanisms of chronic pain. Trends Neurosci. 2015;38(4):237–46. https://doi.org/10.1016/j.tins.2015.02.001.

25. Tagliaferri SD, Miller CT, Owen PJ, Mitchell UH, Brisby H, Fitzgibbon B, et al. Domains of chronic low back pain and assessing treatment effectiveness: a clinical perspective. Pain Pract. 2020;20(2):211–25. https://doi.org/10.1111/papr.12846.

26. Heuch I, Hagen K, Heuch I, Nygaard Ø, Zwart JA. The impact of body mass index on the prevalence of low back pain: the HUNT study. Spine. 2010;35(7):764–8. https://doi.org/10.1097/BRS.0b013e3181ba1531.

27. Goubert D, Oosterwijck JV, Meeus M, Danneels L. Structural changes of lumbar muscles in non-specific low back pain: a systematic review. Pain Phys. 2016;19(7):E985 – E1000. 27676689.

28. Fortin M, Vídean L, Gibbons LE, Battle MC. Paraspinal muscle morphology and composition: a 15-yr longitudinal magnetic resonance imaging study. Med Sci Sports Exerc. 2014;46(5):893–901. https://doi.org/10.1249/MSS.0000000000000179.

29. Yoshimoto T, Ochiai H, Shirasawa T, Nagahama S, Uehara A, Muramatsu J, et al. Clustering of lifestyle factors and its association with low back pain: a cross-sectional study of over 400,000 Japanese adults. J Pain Res. 2020;13:1411–9. https://doi.org/10.2147/JPR.S247529.

30. Senba E, Kami K. A new aspect of chronic pain as a lifestyle-related disease. Neurobiol Pain. 2017;1:15–16. https://doi.org/10.1016/j.jnypa.2017.04.003.

31. Polli A, Ickmans K, Godderis L, Nijs J. When environment meets genetics: a clinical review of the epigenetics of pain, psychological factors, and physical activity. Arch Phys Med Rehabil. 2019;100(6):1153–61. https://doi.org/10.1016/j.japhr.2018.09.118.

32. Lubin FD, Roth TL, Sweett JD. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci. 2008;28(42):10576–86. https://doi.org/10.1523/JNEUROSCI.1786-08.2008.

33. Rainville J, Smeets RJ, Bendix T, Tveito TH, Poiraudeau S, Indahl AJ. Fear-avoidance beliefs and pain avoidance in low back pain–translating research into clinical practice. Spine J. 2011;11(9):e95–903. https://doi.org/10.1016/j.spinee.2011.08.006.

34. Sullivan MJ, Adams H, Rhodenizer T, Stanish WD. A psychosocial risk factor–targeted intervention for the prevention of chronic pain and disability following whiplash injury. Phys Ther. 2006;86(1):18–18. https://doi.org/10.1093/ptj/ptj618.

35. Chapman CR, Tuckett RP, Song CW. Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain. 2008;9(2):122–49. https://doi.org/10.1016/j.jjpain.2007.09.006.

36. Clark JR, Nisj J, Yeowell G, Goodwin PC. Trait sensitivity, anxiety, and personality are predictive of central sensitization symptoms in patients with chronic low back pain. Pain Pract. 2019;19(8):800–10. https://doi.org/10.1111/papr.12809.

37. Clark JR, Yeowell G, Goodwin PC. Trait anxiety and sensory processing profile characteristics in patients with non-specific chronic low back pain and central sensitization - a pilot observational study. J Bodywork Mov Ther. 2018;22(4):909–16. https://doi.org/10.1016/j.jbmt.2017.11.007.

38. Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. Man Ther. 2010;15(3):220–8. https://doi.org/10.1016/j.math.2009.12.004.

39. Nascimento PR, Costa LOP. Prevalência da dor lombar no Brasil: uma revisão sistemática. Cad Saude Publica. 2015;31(6):1141–55. https://doi.org/10.1590/0102-311X00046114.

40. Buchbinder R, Tulder MV, Öberg B, Costa LM, Woolf A, Schoene M, et al. Low back pain: a call for action. Lancet. 2018;391(10137):2384–8. https://doi.org/10.1016/S0140-6736(18)30488-4.

41. Dutchenko L, Fillingim RB, Smith SR, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. Nat Rev Rheumatol. 2013;9(6):340–50. https://doi.org/10.1038/nrrheum.2013.43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.